Hepatitis C: Explore key pipeline products.
By Michael Haydock, Lead Analyst
3 December 2014
I am the Lead Analyst of the immunology and inflammation and infectious diseases and vaccines teams at Datamonitor Healt...
Read full bio
Gilead, AbbVie, Bristol-Myers Squibb, and Merck & Co are each developing all-oral regimens that have shown greatly increased efficacy over interferon-based treatments and are at the head of a new wave of innovation in R&D.
Datamonitor Healthcare has produced a review of key pipeline products, pipeline trends, and future treatment paradigms for hepatitis C across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK). We now also include a chapter on early-phase opportunities within the pipeline.
How will our hepatitis C pipeline report benefit you?
- Identify early-phase opportunities
Access an interactive early-phase forecast model as well as an in-depth analysis of key modes of action, enabling you to identify any investment opportunities within the pipeline.
- Gain a competitive overview
Understand how interferon-free regimens will be positioned by comparing their clinical and commercial attributes, allowing you to benchmark your product against those with the most potential for success.
- Utilize R&D innovations
Explore all R&D innovation currently in the pipeline, including Merck & Co’s C-EDGE and C-SWIFT programs, to understand how they will impact the market, enabling you to adapt your market strategy to remain competitive.
Key questions answered
- What will be the key differentiators for pipeline interferon-free regimens that will assist in their market uptake?
- What unmet needs will companies have to address in order to stay competitive?
- Which mechanisms of action in Phase I and Phase II have the greatest future commercial potential and why?
|Drug List:||Companies Mentioned:|
Posted in Infectious Diseases.